Clindamycin-d₃is intended for use as an internal standard for the quantification of clindamycin by GC- or LC-MS. Clindamycin is a lincosamide antibiotic.^1,2It is active against Gram-positive bacteria, including various strains ofS. pneumoniae,S. viridans,S. aureus, andS. epidermidis(MICs = 0.002-0.1, 0.005-0.2, 0.04-1.6, and 0.1-0.2 µg/ml, respectively).¹Clindamycin is also active against chloroquine-resistant and -sensitive strains ofP. falciparum(IC₅₀s = 3.12 and 8.81 nM, respectively).²It inhibits bacterial protein synthesis by interacting with the 50S ribosome.¹Clindamycin increases survival in a mouse model of a secondaryS. pneumoniaeinfection when administered at a dose of 15 mg/kg twice daily for seven days.³Formulations containing clindamycin have been used in the treatment of bacterial infections.

1.SpÍ?ek, J., and ?ezanka, T.Lincomycin, clindamycin and their applicationsAppl. Microbiol. Biotechnol.64(4)455-464(2004) 2.Dahl, E.L., and Rosenthal, P.J.Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplastAntimicrob. Agents Chemother.51(10)3485-3490(2007) 3.KarlstrÖm, Å., Boyd, K.L., English, B.K., et al.Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenzaJ. Infect. Dis.199(3)311-319(2009)